Antiparasitic and Antibacterial Drug Discovery (PDF)

Preamble Editor Preface PART I Drug Discovery Approaches 1 Target identification and mechanism-based screening for anthelmintics: Application of veterinary antiparasitic research programmes to search for new antiparasitic drugs for human indications 2 Anthelmintic resistance as a guide to the discovery of new drugs? 3 Drug discovery for neglected diseases: view of a public-private partnership 4 Bioinformatics and Chemoinformatics: Key Technologies in the Drug Discovery Process 5 Target identification and validation in anti parasitic drug discovery 6 Selective Drug Targets in Parasites 7 Lessons Learned From Target Based Lead Discovery 8 Approaches towards Antiparasitic Drug Candidates for Veterinary Use 9 Learning to Relate Structural Space with Property Space 10 Recruiting the Host Defense Mechanisms: Roles for Vaccines and Chemotherapeutics PART II Protozoan Parasites 11 Proteases of Parasitic Protozoa - Current Status and Validation 12 In Search of Trypanocidal Drugs 13 Trypanosomatid protein kinases as potential drug targets 14 Targeting the malaria kinome; discovering kinase inhibitors as novel antimalarial agents 15 Malaria and anti-malarials - a focused view PART III Multicellular Parasites 16 Chemotherapeutic development strategies for schistosomiasis 17 Searching new Anti-Parasitics in the Virtual Space 18 Cyclooctadepsipeptides - an anthelmintically active class of compounds exhibiting a novel mode of action 19 Chemical Optimization of Anthelmintic Compounds - a Case Study PART IV Bacteria 20 Pathogenomics: identification of novel drug targets and vaccine candidates in bacteria 21 Tuberculosis Drug Discovery: Issues, Gaps and the Way Forward 22 Decreasing the number of gaps in the draft assembly of the Mannheimia haemolytica M7/2 genome sequence 23 Total synthesis and configurational assignment of pasteurestin A and B, a natural product with antimicrobial acitivty on Pasteurellaceae

Prof. Dr. Paul M. Selzer studied Biology, Parasitology, and Biochemistry at the University of Tübingen, Germany, where he also received his PhD in Biochemistry on subjects related to the protozoan parasite Trypanosoma brucei. As a post-doctoral fellow he spent three years in the parasitology and tropical disease laboratory of Prof. James H. McKerrow at the University of California, San Francisco (UCSF). Within the Molecular Design Institute at UCSF Dr. Selzer was introduced to modern drug discovery approaches and technologies. He broadened his scientific and business knowledge as a researcher within diverse pharmaceutical companies including Boehringer Mannheim GmbH, Germany, SmithKline Beecham p.l.c., UK, Hoechst Roussel Vet GmbH, Germany, and finally Intervet Innovation GmbH, Germany, a part of Intervet/ Schering-Plough Animal Health. Dr. Selzer is also a teacher in Biochemistry, Bioinformatics, and Chemoinformatics at the University of Tübingen in the Department of Biochemistry, which awarded him the title of Professor for his achievements in teaching and research. In 2008, he was also awarded an Honorary Professorship in the Department of Infection and Immunity at the University of Glasgow.

Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.